Clinical Trial Update: Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the effect of Biejia-Ruangan Compound on survival and recurrence after radical treatment in hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Biejia-Ruangan Compound

Snippet

Sponsor: Zhiyun Yang | Conditions: Hepatocellular Carcinoma (HCC) | Phase 4 | Status: NOT_YET_RECRUITING